Fate Therapeutics, Inc. (FATE - Free Report) was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $12.29 to $15.10 in the past one-month time frame.
The move came after the company announced that the FDA has given clearance to its Investigational New Drug Application for FT500.
The company's Zacks Consensus Estimate for the current quarter has moved higher over the past few weeks, suggesting that more solid trading could be ahead for Tailored Brands. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Fate Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
Fate Therapeutics, Inc. Price
Investors interested in the Medical – Biomedical and Genetics industry may consider Alexion Pharmaceuticals, Inc. (ALXN - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is FATE going up? Or down? Predict to see what others think:Up or Down
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>